Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue

Prostate

Volumn 66, Issue 1, 2006, Pages 13-18

  Hudolin, Tvrtko ^a,e   Juretic, Antonio ^a   Spagnoli, Giulio Cesare ^b   Pasini, Josip ^a   Bandic, Daniela ^c   Heberer, Michael ^b   Kosicek, Miljenko ^d   Cacic, Mirjana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF BASEL   (Switzerland)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d Klinika za Urologiju ^*

^e KBC Zagreb   (Croatia)

Author keywords

MAGE A1; MAGE A3 4; NY ESO 1; Prostate cancer; Tumor antigens

Indexed keywords

CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; NY ESO 1 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 29344471439     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20312     Document Type: Article

References (22)

1. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: Identification, expression profile, and putative function. J Cell Physiol 2003;194:272-288.
2. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. Eur J Cancer 2003;39:70-77.
3. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-1678.
4. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
5. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, Heberer M, Sauter G, Spagnoli GC. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. Int J Cancer 2002;100:702-705.
6. Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Kollermann MW, Pantel K, Riethmuller G. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: A novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002;62:251-261.
7. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-1918.
8. Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003;31:3-10.
9. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004;59:440-447.
10. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: Immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003;4:104-109.
11. Greene FL, Page DL, Fleming ID, editors. Prostate. AJCC Cancer Staging Manual, 6th edition. New York: Springer Verlag; 2002. 309p.
12. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. WHO Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.179p.
13. Schultz-Thater E, Juretic A, Dellabona P, Luscher U, Siegrist W, Harder F, Heberer M, Zuber M, Spagnoli GC. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer 1994;59:435-439.
14. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-2239.
15. Schultz-Thater E, Noppen C, Gudat F, Durmuller U, Zajac P, Kocher T, Heberer M, Spagnoli GC. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000;83:204-208.
16. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-693.
17. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-860.
18. Fischer C, Gudat F, Stulz P, Noppen C, Schaefer C, Zajac P, Trutmann M, Kocher T, Zuber M, Harder F, Heberer M, Spagnoli GC. High expression of MAGE-3 protein in squamous-cell lung carcinoma. Int J Cancer 1997;71:1119-1121.
19. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996;93:7149-7153.
20. Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998;273:17618-17625.
21. Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003;14:1497-1510.
22. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004;64:2199-2204.